Since 2020, YJ Biotechnology has been transforming regenerative medicine with its cost-efficient, internationally-certified and decentralized one-stop cell manufacturing platform supporting industrial...

Hematopoietic stem cells (HSCs) maintain their self-renewal capacity in an autocrine manner through hematopoietic stem and progenitor cell (HSPC)-derived extracellular vesicles (EVs). Here, we present a protocol for the isolation and characterization of EVs from HSPCs starting from an in vivo murine model. We describe steps for murine bone marrow isolation, HSPC staining and sorting, HSPC-derived EV isolation, size and concentration characterization, and EV visualization and marker description. ...

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

Nanozymes spark attention as emerging nanotherapeutics due to their impressive medicinal potential across a wide range of diseases. Nevertheless, beyond therapeutic efficacy, nanomedicines must undergo rigorous safety assessment to ensure successful clinical translation. This comprehensive review outlines the current safety landscape of therapeutic nanozymes and highlights future research directions aimed at enhancing the current safety assessment. Abstract Oxidative stress and inflammation are at the root of a multitude of diseases. Treatment of these conditions is often necessary but current standard therapies to fight excessive reactive oxygen species (ROS) and inflammation are often ineffective or complicated by substantial safety concerns. Nanozymes are emerging nanomaterials with intrinsic enzyme-like properties that hold great promise for effective cancer treatment, bacterial elimination, and anti-inflammatory/anti-oxidant therapy. While there is rapid progress in tailoring their catalytic activities as evidenced by the recent integration of single-atom catalysts (SACs) to create next-generation nanozymes with superior activity, selectivity, and stability, a better understanding and tuning of their safety profile is imperative for successful clinical translation. This review outlines the current applied safety assessment approaches and provides a comprehensive summary of the safety knowledge of therapeutic nanozymes. Overall, nanozymes so far show good in vitro and in vivo biocompatibility despite considerable differences in their composition and enzymatic activities. However, current safety investigations mostly cover a limited set of basic toxicological endpoints, which do not allow for a thorough and deep assessment. Ultimately, remaining research gaps that should be carefully addressed in future studies are highlighted, to optimize the safety profile of therapeutic nanozymes early in their pre-clinical development.

Hybrid capture is a critical technology for selective enrichment of genomic regions of interest, enabling cost-effective focused sequencing in both clinical and research applications. We present a sim...

Noninvasive blood detection of brain-derived vesicles enables early and precise diagnosis of brain diseases.

EV vaccines can be engineered to be loaded with antigenic proteins and antigen-encoding RNAs by genetic engineering of parental cells or direct engineering of EVs. Due to possessing many of the key immunostimulatory properties of donor cells, EVs are capable of activating immune responses for vaccination against infectious diseases and cancers by direct antigen-presentation, semi-direct antigen-presentation, and indirect antigen-presentation pathways.